Literature DB >> 7665250

Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder.

J J Patard1, F Brasseur, S Gil-Diez, F Radvanyi, M Marchand, P François, A Abi-Aad, P Van Cangh, C C Abbou, D Chopin.   

Abstract

Human genes MAGE-1 and MAGE-3 code for distinct antigens, which are recognized on melanoma cells by autologous cytolytic T lymphocytes (CTL). These antigens may constitute useful targets for anti-cancer immunotherapy, since no expression of MAGE genes has been observed in normal tissues other than testis. Out of 57 samples of primary transitional-cell carcinomas of the bladder, 12 (21%) expressed MAGE-1 and 20 (35%) expressed MAGE-3. All but one of the tumors expressing MAGE-1 also expressed MAGE-3. Genes MAGE-2 and MAGE-4, which are closely related to MAGE-1 and MAGE-3, were expressed by 30% and 33% of the tumors respectively. MAGE expression was more frequent in advanced tumor stages: 61% of the invasive tumors (stage > or = T2) were positive for expression of at least one of the four genes, whereas only 28% of the superficial tumors (stages Ta and T1) expressed these genes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7665250     DOI: 10.1002/ijc.2910640112

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  31 in total

1.  Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.

Authors:  S J Pettit; S Ali; E O'Flaherty; T R Griffiths; D E Neal; J A Kirby
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

Review 2.  Cancer/testis antigens and urological malignancies.

Authors:  Prakash Kulkarni; Takumi Shiraishi; Krithika Rajagopalan; Robert Kim; Steven M Mooney; Robert H Getzenberg
Journal:  Nat Rev Urol       Date:  2012-06-19       Impact factor: 14.432

Review 3.  Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens.

Authors:  P Romero
Journal:  Springer Semin Immunopathol       Date:  1996

4.  Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics.

Authors:  Evelyne Lerut; Hendrik Van Poppel; Steven Joniau; Olivier Gruselle; Thierry Coche; Patrick Therasse
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

5.  Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1.

Authors:  H Büeler; R C Mulligan
Journal:  Mol Med       Date:  1996-09       Impact factor: 6.354

6.  MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases.

Authors:  Jennifer M Doyle; Jinlan Gao; Jiawei Wang; Maojun Yang; Patrick Ryan Potts
Journal:  Mol Cell       Date:  2010-09-24       Impact factor: 17.970

Review 7.  Human spermatogonial stem cells: a possible origin for spermatocytic seminoma.

Authors:  R Waheeb; M-C Hofmann
Journal:  Int J Androl       Date:  2011-08

8.  Expression of MAGE tumor-associated antigen in thyroid carcinomas.

Authors:  Marija Milkovic; Bozena Sarcevic; Elizabet Glavan
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

9.  Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas.

Authors:  Anne-Katrin Zimmermann; Jochen Imig; Agnes Klar; Christoph Renner; Dimitri Korol; Daniel Fink; Sylvia Stadlmann; Gad Singer; Alexander Knuth; Holger Moch; Rosmarie Caduff
Journal:  Virchows Arch       Date:  2013-03-26       Impact factor: 4.064

10.  Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.

Authors:  Brian J Cameron; Andrew B Gerry; Joseph Dukes; Jane V Harper; Vivekanandan Kannan; Frayne C Bianchi; Francis Grand; Joanna E Brewer; Minnal Gupta; Gabriela Plesa; Giovanna Bossi; Annelise Vuidepot; Alex S Powlesland; Alison Legg; Katherine J Adams; Alan D Bennett; Nicholas J Pumphrey; Daniel D Williams; Gwendolyn Binder-Scholl; Irina Kulikovskaya; Bruce L Levine; James L Riley; Angel Varela-Rohena; Edward A Stadtmauer; Aaron P Rapoport; Gerald P Linette; Carl H June; Namir J Hassan; Michael Kalos; Bent K Jakobsen
Journal:  Sci Transl Med       Date:  2013-08-07       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.